Prediction of chemotherapy-mediated cardiotoxicity in patients with cancer by cardiac troponin I: A systematic review and meta-analysis.

IF 0.8 Q4 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Yang Liu, Huanglong Liu
{"title":"Prediction of chemotherapy-mediated cardiotoxicity in patients with cancer by cardiac troponin I: A systematic review and meta-analysis.","authors":"Yang Liu, Huanglong Liu","doi":"10.1177/09246479241302586","DOIUrl":null,"url":null,"abstract":"<p><p>BackgroundCardiac damage is a significant risk of chemotherapy. Elevated circulating cardiac troponin I was suggested as a marker for early detection of cardiac damage.ObjectiveWe aim to assess the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients.MethodsWe searched PubMed, Web of Science, Embase, and CNKI. Nine prospective studies involving 2033 cancer patients (pts) were included in the meta-analysis. Troponin I (TnI) levels in patients who underwent chemotherapy were categorized into cardiac troponin I (cTnI) positive and negative groups based on the cutoff concentrations described in the included studies. The cumulative effects of chemotherapy-induced cardiotoxicity between the cTnI-positive and cTnI-negative patients were represented as a summarized risk difference (RD) value with a 95% confidence interval. Subgroup analysis and sensitivity analysis were employed to address heterogeneities. Stata software (version 12.0) was utilized for the analysis.ResultscTnI-positive pts represented significant cardiotoxicity compared to cTnI-negative pts, as a decline in left ventricular ejection fraction (LVEF): RD = 0.279 [95% CI (0.248-0.311), <i>p</i> = 0.000, I<sup>2</sup> = 81.3%, 8 trials], heart failure (HF): RD = 0.117, [95% CI (0.090-0.144), <i>p</i> = 0.000, I<sup>2</sup> = 77.8%, 6 trials], arrhythmias: RD = 0.057 [95% CI (0.028-0.086), <i>p</i> = 0.000, I<sup>2</sup> = 0.0%, 3 trials], and cumulative events: RD = 0.318 [95% CI (0.272-0.364), <i>p</i> = 0.000, I<sup>2</sup> = 73.5%, 3 trials]. No statistically significant difference in cardiac death, acute pulmonary edema, and acute coronary syndromes between cTnI-positive pts and cTnI-negative pts was identified.ConclusionsAn increase in circulating troponin I serve as a potential biomarker that reflecting the high risk of early cardiotoxicity in cancer patients who have undergone chemotherapy. The presence of intrinsic unadjusted confounding factors in the reports suggests the need for further study to address this question.</p>","PeriodicalId":45237,"journal":{"name":"INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE","volume":" ","pages":"26-48"},"PeriodicalIF":0.8000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/09246479241302586","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/24 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

BackgroundCardiac damage is a significant risk of chemotherapy. Elevated circulating cardiac troponin I was suggested as a marker for early detection of cardiac damage.ObjectiveWe aim to assess the predictive value of cardiac troponin I for chemotherapy-induced cardiotoxicity in cancer patients.MethodsWe searched PubMed, Web of Science, Embase, and CNKI. Nine prospective studies involving 2033 cancer patients (pts) were included in the meta-analysis. Troponin I (TnI) levels in patients who underwent chemotherapy were categorized into cardiac troponin I (cTnI) positive and negative groups based on the cutoff concentrations described in the included studies. The cumulative effects of chemotherapy-induced cardiotoxicity between the cTnI-positive and cTnI-negative patients were represented as a summarized risk difference (RD) value with a 95% confidence interval. Subgroup analysis and sensitivity analysis were employed to address heterogeneities. Stata software (version 12.0) was utilized for the analysis.ResultscTnI-positive pts represented significant cardiotoxicity compared to cTnI-negative pts, as a decline in left ventricular ejection fraction (LVEF): RD = 0.279 [95% CI (0.248-0.311), p = 0.000, I2 = 81.3%, 8 trials], heart failure (HF): RD = 0.117, [95% CI (0.090-0.144), p = 0.000, I2 = 77.8%, 6 trials], arrhythmias: RD = 0.057 [95% CI (0.028-0.086), p = 0.000, I2 = 0.0%, 3 trials], and cumulative events: RD = 0.318 [95% CI (0.272-0.364), p = 0.000, I2 = 73.5%, 3 trials]. No statistically significant difference in cardiac death, acute pulmonary edema, and acute coronary syndromes between cTnI-positive pts and cTnI-negative pts was identified.ConclusionsAn increase in circulating troponin I serve as a potential biomarker that reflecting the high risk of early cardiotoxicity in cancer patients who have undergone chemotherapy. The presence of intrinsic unadjusted confounding factors in the reports suggests the need for further study to address this question.

通过心肌肌钙蛋白I预测癌症患者化疗介导的心脏毒性:一项系统回顾和荟萃分析。
背景:心脏损伤是化疗的重要风险。循环心肌肌钙蛋白I升高被认为是早期发现心脏损伤的标志。目的:评估心肌肌钙蛋白I对癌症患者化疗引起的心脏毒性的预测价值。方法:检索PubMed、Web of Science、Embase、CNKI。meta分析纳入了涉及2033名癌症患者的9项前瞻性研究。化疗患者的肌钙蛋白I (TnI)水平根据纳入的研究中描述的截止浓度分为心肌肌钙蛋白I (cTnI)阳性和阴性组。ctni阳性和ctni阴性患者之间化疗诱导的心脏毒性的累积效应以汇总风险差异(RD)值表示,其置信区间为95%。采用亚组分析和敏感性分析分析异质性。采用Stata软件(12.0版本)进行分析。结果:cTnI-positive分代表重要毒性cTnI-negative分相比,作为减少左心室射血分数(LVEF): RD = 0.279(95%可信区间(0.248 - -0.311),p = 0.000, I2 = 81.3%, 8个试验),心力衰竭(HF): RD = 0.117(95%可信区间(0.090 - -0.144),p = 0.000, I2 = 77.8%, 6试验),心律失常:RD = 0.057(95%可信区间(0.028 - -0.086),p = 0.000, I2 = 0.0%, 3个试验),和累积事件:RD = 0.318(95%可信区间(0.272 - -0.364),p = 0.000, I2 = 73.5%, 3试验]。ctni阳性患者与ctni阴性患者在心源性死亡、急性肺水肿和急性冠状动脉综合征方面无统计学差异。结论:循环肌钙蛋白I的增加作为一种潜在的生物标志物,反映了接受化疗的癌症患者早期心脏毒性的高风险。报告中存在内在的未经调整的混杂因素,这表明需要进一步研究以解决这个问题。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE
INTERNATIONAL JOURNAL OF RISK & SAFETY IN MEDICINE PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
2.20
自引率
17.60%
发文量
102
期刊介绍: The International Journal of Risk and Safety in Medicine is concerned with rendering the practice of medicine as safe as it can be; that involves promoting the highest possible quality of care, but also examining how those risks which are inevitable can be contained and managed. This is not exclusively a drugs journal. Recently it was decided to include in the subtitle of the journal three items to better indicate the scope of the journal, i.e. patient safety, pharmacovigilance and liability and the Editorial Board was adjusted accordingly. For each of these sections an Associate Editor was invited. We especially want to emphasize patient safety.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信